undamentalytics Newsletter

Brown Jeffrey J: insider trades

Director at 2 companies we cover. 44 open-market purchases and 1 sale not made under a pre-set plan, reported from November 14, 2016 to October 29, 2026.

Would copying Brown Jeffrey J’s purchases have beaten the S&P 500?

Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on November 15, 2016 into $17,885 by November 2, 2026, +6.0% a year. The copy held shares only 75% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $35,457, +13.6% a year (the S&P 500 held throughout made $40,582, +15.2% a year). Beta against the index was 0.68. Twelve months after each report, the average purchase was −23.6% against the S&P 500 (median −34.5%), and 23% beat it: within what luck alone would produce (p = 0.72 over 7 years). Measured from the trade date, the insider’s own timing, the average was −23.2%. After their sales, the shares moved −106.6% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k$60.0k 201620182020202220242026 $40.6k$35.5k$17.9k
Copying Brown Jeffrey JS&P 500, same days investedS&P 500, held throughout $10,000 copying Brown Jeffrey J’s open-market purchases from November 15, 2016, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+6.0%
S&P 500, same days invested
+13.6% (held throughout +15.2%)
Time in shares
75%
Sharpe ratio (S&P 500)
0.27 (0.73)
Biggest drop (S&P 500)
−80% (−34%)
Market sensitivity (beta)
0.68
Purchases copied
44

Trade by trade

Brown Jeffrey J: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 43 −3.9% −7.1% 33% 8 −0.12 0.91 No reliable evidence
Purchases, 6 months after the report 42 −10.9% −14.5% 26% 8 −0.59 0.57 No reliable evidence
Purchases, 12 months after the report 40 −23.6% −34.5% 23% 7 −0.38 0.72 No reliable evidence
Purchases, 12 months after the trade 40 −23.2% −32.2% 23% 8 0.31 0.77 No reliable evidence
Sales, 3 months after the report 1 −20.7% −20.7% 100% 1 — — Not enough years
Sales, 12 months after the report 1 −106.6% −106.6% 100% 1 — — Not enough years
Sales, 12 months after the trade 1 −102.4% −102.4% 100% 1 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Upbound Group, Inc. UPBD —270May 11, 2020October 29, 2026
Medifast Inc MED —171November 14, 2016November 9, 2023

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
October 29, 2026October 27, 2026 UPBD Purchase $47,016 not yetnot yetnot yet
July 9, 2026July 7, 2026 UPBD Purchase $46,107 −26.7%not yetnot yet
April 30, 2026April 28, 2026 UPBD Purchase $45,206 +2.6%not yetnot yet
January 8, 2026January 6, 2026 UPBD Purchase $44,235 −3.4%not yetnot yet
October 23, 2025October 21, 2025 UPBD Purchase $43,449 −16.2%−33.3%−32.0%
July 9, 2025July 8, 2025 UPBD Purchase $42,813 −26.5%−35.6%−38.4%
May 7, 2025May 6, 2025 UPBD Purchase $516,088 −21.6%−51.5%−45.7%
April 23, 2025April 22, 2025 UPBD Purchase $33,694 +6.0%−32.6%−33.3%
January 10, 2025January 7, 2025 UPBD Purchase $33,245 −19.2%−48.1%−46.9%
October 24, 2024October 22, 2024 UPBD Purchase $31,151 +7.9%−28.5%−32.4%
July 11, 2024July 9, 2024 UPBD Purchase $30,744 −9.5%−28.6%−19.6%
April 24, 2024April 22, 2024 UPBD Purchase $30,404 +9.3%−43.7%−40.5%
January 11, 2024January 9, 2024 UPBD Purchase $30,041 −9.5%−31.6%−30.7%
November 9, 2023November 3, 2023 MED Purchase $10,845 −31.7%−107.6%−105.3%
October 26, 2023October 24, 2023 UPBD Purchase $27,279 +19.2%−32.9%−29.2%
August 16, 2023August 14, 2023 MED Sale $3,492,041 −20.7%−106.6%−102.4%
August 10, 2023August 4, 2023 MED Purchase $72,857 −27.2%−102.6%−97.6%
July 13, 2023July 11, 2023 UPBD Purchase $26,994 −6.6%−18.2%−24.4%
May 11, 2023May 5, 2023 MED Purchase $68,978 −3.3%−98.0%−98.0%
April 26, 2023April 24, 2023 UPBD Purchase $26,609 +19.9%−0.4%+17.7%
February 9, 2023February 3, 2023 MED Purchase $67,607 −16.8%−70.6%−72.4%
January 12, 2023January 10, 2023 UPBD Purchase $26,233 −8.1%+14.2%+16.4%
November 10, 2022November 4, 2022 MED Purchase $60,205 −4.8%−51.9%−49.2%
October 27, 2022October 25, 2022 UPBD Purchase $25,739 +27.3%+23.7%+25.5%
August 11, 2022August 9, 2022 MED Purchase $498,549 −7.6%−35.6%−32.8%
August 10, 2022August 4, 2022 MED Purchase $58,281 −9.3%−33.8%−41.4%
July 14, 2022July 12, 2022 UPBD Purchase $25,304 −0.4%+46.3%+43.5%
May 11, 2022May 5, 2022 MED Purchase $57,768 −30.3%−51.8%−49.7%
April 26, 2022April 22, 2022 UPBD Purchase $24,985 +2.7%+19.6%+9.0%
April 21, 2022February 4, 2022 MED Purchase $49,640 +4.2%−43.0%−30.0%
January 14, 2022January 13, 2022 UPBD Purchase $24,796 −37.3%−29.3%−29.5%
November 10, 2021November 8, 2021 MED Purchase $973,911 −11.2%−35.2%−30.9%
November 9, 2021November 8, 2021 UPBD Purchase $1,069,790 −10.2%−33.9%−31.7%
October 20, 2021October 19, 2021 UPBD Purchase $14,980 −24.0%−50.7%−49.2%
August 10, 2021August 6, 2021 MED Purchase $40,675 −11.2%−39.0%−40.4%
July 14, 2021July 13, 2021 UPBD Purchase $14,892 +0.8%−47.1%−46.7%
May 10, 2021May 6, 2021 MED Purchase $40,422 −25.2%−36.0%−29.5%
April 23, 2021April 22, 2021 UPBD Purchase $14,807 −7.1%−59.4%−59.2%
March 31, 2021February 26, 2021 UPBD Purchase $1,499,898 −14.8%−70.5%−64.6%
February 9, 2021February 5, 2021 MED Purchase $32,016 −2.4%−45.8%−40.4%
November 10, 2020November 6, 2020 MED Purchase $31,792 +51.7%+5.8%−6.0%
August 12, 2020August 4, 2020 MED Purchase $30,093 −2.9%+11.7%+33.7%
May 11, 2020May 8, 2020 UPBD Purchase $460,200 +30.4%+114.5%+116.6%
May 8, 2020November 9, 2017 MED Purchase $94,890 +69.4%+190.1%+124.9%
November 14, 2016November 9, 2016 MED Purchase $387,100 +6.8%+55.6%+62.9%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Brown Jeffrey J traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.